Kalaris Therapeutics (KLRS) Retained Earnings (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Retained Earnings of $239.5 million for Q1 2026, up 25.62% year-over-year from $190.6 million in Q1 2025, and up 249.66% quarter-over-quarter from -$160.0 million in Q4 2025.
Kalaris Therapeutics (KLRS) Retained Earnings (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at $239.5 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 25.62% year-over-year to $239.5 million; the TTM figure through Mar 2026 stood at $239.5 million (up 25.62% YoY), while the FY2025 annual figure was -$160.0 million, down 37.22% from the prior year.
- Retained Earnings for Q1 2026 stood at $239.5 million, up from -$160.0 million in the prior quarter.
- The five-year high for Retained Earnings was $813.0 million in Q2 2024, with the low at -$696.7 million in Q3 2024.
- The 5-year median for Retained Earnings is -$200000.0 (2023), against an average of $23.8 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings tumbled 348247.0% in 2024, then surged 138236.96% in 2025.
- Kalaris Therapeutics' Retained Earnings stood at $690.8 million in 2022, then tumbled by 100.01% to -$62000.0 in 2023, then sank by 187964.52% to -$116.6 million in 2024, then plunged by 37.22% to -$160.0 million in 2025, then soared by 249.66% to $239.5 million in 2026.
- Business Quant data shows KLRS's Retained Earnings at $239.5 million in Q1 2026, -$160.0 million in Q4 2025, and $191.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Kalaris Therapeutics | 98.28 Mn | 98.28 Mn | - | 240.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 240.11 Mn |
| Mar 31, 2026 | 239.46 Mn |
| Dec 31, 2025 | -160.00 Mn |
| Sep 30, 2025 | 191.86 Mn |
| Jun 30, 2025 | 191.22 Mn |
| Mar 31, 2025 | 190.63 Mn |
| Dec 31, 2024 | -116.60 Mn |
| Sep 30, 2024 | -696.69 Mn |
| Jun 30, 2024 | 812.99 Mn |
| Mar 31, 2024 | -138,000.00 |
| Dec 31, 2023 | -62,000.00 |
| Sep 30, 2023 | -200,000.00 |
| Jun 30, 2023 | -552.20 Mn |
| Mar 31, 2023 | -301,000.00 |
| Dec 31, 2022 | 690.75 Mn |
| Sep 30, 2022 | -563,000.00 |
| Jun 30, 2022 | -444,000.00 |
| Mar 31, 2022 | -385.60 Mn |
| Dec 31, 2021 | -297.07 Mn |
| Sep 30, 2021 | -239.12 Mn |